Literature DB >> 16174099

Polymorphisms of CARD15/NOD2 and CD14 genes in New Zealand Crohn's disease patients.

Euphemia Leung1, Jiwon Hong, Alan G Fraser, Tony R Merriman, Prakash Vishnu, William G H Abbott, Geoffrey W Krissansen.   

Abstract

Polymorphisms in the CARD15/NOD2 gene, which encodes a cytosolic protein involved in bacterial recognition, are associated with development of Crohn's disease (CD). Other potential susceptibility genes such as CD14 may compound the risk of developing CD. We examined the frequency of the three major CARD15 risk alleles (3020insC/L1007fsinsC, G908R and R702W), and a functional polymorphism (-159C/T) in the promoter of the CD14 gene in 185 CD patients in New Zealand and 187 ethnically matched controls. The frequencies of the 3020insC (8.1 vs 0.8%, P < 0.0001), G908R (3.5 vs 2.4%, P = 0.37) and R702W (7.3 vs 5.1%, P = 0.21) alleles in CD patients and controls, respectively, were similar to those described in Australia, and the ancestral countries of Scotland, Ireland and the UK. Only the 3020insC polymorphism was found to be a significant risk factor for CD in our New Zealand cohort (odds ratio = 10.91 [95% confidence intervals 3.30-36.08]; P < 0.0001 for heterozygotes), but not a single patient was homozygous for the 3020insC polymorphism. The T allele (51 vs 50%, P = 0.77) and TT genotype (26 vs 24%, P = 0.84) frequencies of the -159C/T CD14 gene promoter polymorphism did not significantly differ between CD patients and controls. In summary, our findings provide evidence that the CARD15 3020insC risk allele influences disease susceptibility in a small proportion (<17%) of New Zealand CD patients, whereas there was no evidence that the CD14 -159C/T polymorphism is associated with CD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16174099     DOI: 10.1111/j.1440-1711.2005.01362.x

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  6 in total

Review 1.  Role of the intestinal barrier in inflammatory bowel disease.

Authors:  Mike G Laukoetter; Porfirio Nava; Asma Nusrat
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

Review 2.  NOD2: ethnic and geographic differences.

Authors:  Juleen Cavanaugh
Journal:  World J Gastroenterol       Date:  2006-06-21       Impact factor: 5.742

3.  Polymorphisms in genes related to bacterial lipopolysaccharide/peptidoglycan signaling and gastric precancerous lesions in a population at high risk for gastric cancer.

Authors:  Ikuko Kato; Federico Canzian; Martyn Plummer; Silvia Franceschi; Leen-Jan van Doorn; Jorge Vivas; Gladys Lopez; Yanhui Lu; Lydie Gioia-Patricola; Richard K Severson; Ann G Schwartz; Nubia Muñoz
Journal:  Dig Dis Sci       Date:  2006-12-14       Impact factor: 3.487

4.  Association between toll-like receptors/CD14 gene polymorphisms and inflammatory bowel disease in Korean population.

Authors:  Eun Jung Kim; Woo Chul Chung; Kang-Moon Lee; Chang Nyol Paik; Sung Hoon Jung; Bo In Lee; Hiun Suk Chae; Kyu Yong Choi
Journal:  J Korean Med Sci       Date:  2011-12-19       Impact factor: 2.153

Review 5.  The Effectiveness of Probiotics in the Treatment of Inflammatory Bowel Disease (IBD)-A Critical Review.

Authors:  Dominika Jakubczyk; Katarzyna Leszczyńska; Sabina Górska
Journal:  Nutrients       Date:  2020-07-02       Impact factor: 5.717

6.  Association between CD14 gene C-260T polymorphism and inflammatory bowel disease: a meta-analysis.

Authors:  Zhengting Wang; Jiajia Hu; Rong Fan; Jie Zhou; Jie Zhong
Journal:  PLoS One       Date:  2012-09-26       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.